相关临床试验
12
7 进行中
药物批准
96
批准总数
监管机构
3
监管机构数
成立时间
N/A
进行中（未招募）
6
50.0%
已完成
3
25.0%
尚未招募
1
8.3%
招募中
2
16.7%
- Regeneron Pharmaceuticals has begun a Phase 1 trial of REGN20934, an injectable drug candidate for adults with overweight or obesity. - The randomized, double-blind, placebo-controlled study evaluates single ascending doses, focusing on safety, tolerability and pharmacokinetics. - The trial was first submitted on May 11, 2026, and its ClinicalTrials.gov listing was last updated on September 23, 2026, under NCT07594093. - The early-stage program positions Regeneron in the obesity treatment field alongside established players Novo Nordisk and Eli Lilly.
- Eli Lilly has stopped development of a new GLP-1 weight-loss drug candidate after its efficacy fell short of the company's internal expectations. - Mounjaro and Zepbound accounted for nearly 65% of Lilly's top line in the second quarter of 2026, a reliance that rises above 65% with the GLP-1 pill Foundayo. - Lilly is using GLP-1 cash flow to fund in-house research and acquisitions, including three deals announced in one day that moved it into infectious disease. - Since announcing its infectious disease entry in May, Lilly has disclosed two further acquisitions, a pace the company is using to broaden its pipeline before GLP-1 patents expire.
- Florida Attorney General James Uthmeier filed suit against Eli Lilly, Novo Nordisk and Sanofi plus pharmacy benefit managers CVS Caremark, Express Scripts and OptumRx over insulin pricing. - The complaint alleges manufacturers raised published list prices and paid rebates to PBMs for preferred formulary placement, leaving patients tied to list prices paying more. - The state brings two counts under Florida's Deceptive and Unfair Trade Practices Act and one under the Florida Antitrust Act, seeking injunction, restitution, disgorgement, damages and penalties. - About 2.3 million Florida adults have diagnosed diabetes, and patients who are uninsured, in a deductible or paying coinsurance are most exposed to list prices.
- Novo Nordisk has signed a global licensing agreement worth up to 1.165 billion euros ($1.33 billion) to apply Nanexa's PharmaShell drug-delivery technology to its obesity and type 2 diabetes medicines. - The deal grants Novo exclusive rights to use PharmaShell across up to five development programs, with the companies targeting monthly and quarterly dosing instead of current regimens. - PharmaShell applies an ultra-thin inorganic coating to drug particles that forms a depot at the injection site, releasing drug into the bloodstream as the coating dissolves. - The agreement follows Novo's stated plan to advance a once-monthly GLP-1 candidate into the clinic this year, with three or four first human doses expected within a year.
- Roche's once-weekly dual GLP-1/GIP agonist enicepatide met both primary endpoints in a 447-patient Phase II study in type 2 diabetes with overweight or obesity. - At the 24 mg dose, HbA1c fell 2.65% from a baseline of 8.1% and mean body weight dropped 15.5% at 48 weeks with no plateau. - About 90% of patients reached HbA1c of 6.5% or lower and 62% achieved normoglycemia, while gastrointestinal side effects were mostly mild to moderate. - Roche has two Phase III chronic weight management trials underway and plans Phase III glycemic-control and cardiovascular outcomes studies in the first half of 2027.
- Eli Lilly CEO Dave Ricks said 700,000 newly enrolled seniors have started GLP-1 therapy since Medicare began covering obesity drugs in July. - Roughly 70% of those new Medicare patients are taking Lilly medicines, with injectable Zepbound the main driver of that share. - Coverage runs through a temporary program called Bridge, which offers eligible beneficiaries weight loss drugs for a $50 monthly co-pay. - One-third of new oral GLP-1 starts under the program are for Lilly's Foundayo, which launched in April behind Novo Nordisk's oral Wegovy.
- Novo Nordisk reported that CagriSema produced an estimated 12.4% body weight loss versus 9.1% for patients receiving Eli Lilly's tirzepatide in a late-stage diabetes study. - The trial tested tirzepatide at its 5-milligram dose rather than higher approved doses, and enrolled people with diabetes, limiting how the headline gap can be interpreted. - Novo Nordisk also reported non-inferior blood-sugar reduction for CagriSema against the Lilly comparator in the same study. - CagriSema previously lost to Zepbound in an obesity-focused head-to-head trial, and Novo Nordisk expects a US FDA weight-management decision in the fourth quarter.
- Novo Nordisk reported that CagriSema produced an estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes. - A 1 mg dose of CagriSema was superior to 5 mg tirzepatide for weight loss, which achieved 9.1% in the same head-to-head study. - CagriSema also demonstrated non-inferior blood sugar reduction versus tirzepatide in patients with diabetes, and a separate late-stage obesity study showed 21% weight loss versus placebo. - Novo Nordisk is targeting an early 2026 launch for the CagriSema combination, with an FDA decision on its weight management application expected in the fourth quarter.
- Novo Nordisk told its Capital Markets Day in London it aims to launch more than five blockbuster drugs by 2030 and generate over 150 billion Danish kroner in pipeline sales by 2035. - The company detailed a staged obesity injectable rollout: CagriSema launch targeted for early next year, standalone cagrilintide and high-dose CagriSema in 2028, then zenagamtide. - Novo aims to reach more than 60 million patients globally by 2030 and scale manufacturing tenfold to supply 15 million patients with oral obesity therapies by decade's end. - Semaglutide, the active ingredient in Ozempic and Wegovy, has lost patent exclusivity in Canada, India, Brazil and Turkey this year, with Europe and the U.S. running into the early 2030s.
- Novo Nordisk has acquired three early-stage obesity programs from New York-based Kallyope, deepening a relationship that began with a 2024 research collaboration and single-asset license. - The lead asset, once-weekly peptide K-554, targets a previously undisclosed neural circuit component in feeding regulation and is distinct from GLP-1 and amylin biology. - The two remaining programs are small molecules against separate novel targets and are currently in lead optimization, with no financial terms disclosed. - The deal adds a neural-circuits discovery axis to a Novo obesity pipeline that already spans GLP-1, amylin, CB1 inverse agonist and multi-receptor agonist approaches.
